ストックスクリーナーアプリを入手
14.13
0.60%
-0.135
前日終値:
$14.00
開ける：
$13.96
24時間の取引高:
55,417
Relative Volume:
0.18
時価総額：
$244.21M
収益：
-
当期純損益:
$-52.60M
株価収益率:
-10.58
EPS:
-1.3361
ネットキャッシュフロー:
$-35.80M
1週間 パフォーマンス:
-6.67%
1か月 パフォーマンス:
+18.43%
6か月 パフォーマンス:
+91.67%
1年 パフォーマンス:
+126.93%
1日の値動き範囲:
$13.74
$14.44
1週間の範囲:
$13.22
$15.33
52週間の値動き範囲:
$4.63
$18.38
Tenax Therapeutics Inc Stock (TENX) Company Profile
名前
Tenax Therapeutics Inc
セクター
電話
919-855-2100
住所
101 GLEN LENNOX DRIVE, CHAPEL HILL, NC
Compare TENX vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TENX
Tenax Therapeutics Inc
|
14.20 | 240.77M | 0 | -52.60M | -35.80M | -1.3361 |
VRTX
Vertex Pharmaceuticals Inc
|
455.43 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.21 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
331.19 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.53 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.68 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Tenax Therapeutics Inc Stock (TENX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-17 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-09-08 | 開始されました | Piper Sandler | Overweight |
| 2024-10-24 | 開始されました | Leerink Partners | Outperform |
| 2024-10-14 | 開始されました | Guggenheim | Buy |
| 2024-09-30 | 開始されました | William Blair | Outperform |
| 2017-05-18 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2014-12-16 | 開始されました | MLV & Co | Buy |
| 2014-11-18 | 開始されました | WallachBeth | Buy |
すべてを表示
Tenax Therapeutics Inc (TENX) 最新ニュース
Tenax Therapeutics (NASDAQ:TENX) Stock Price Passes Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
How (TENX) Movements Inform Risk Allocation Models - Stock Traders Daily
Tenax Therapeutics may offer up to $300 million of securities - marketscreener.com
Tenax Therapeutics May Offer Up To $300 Million Of Securities - TradingView
Tenax Therapeutics (NASDAQ: TENX) registers $300M shelf to sell securities - Stock Titan
Tenax wins bullish view at Cantor ahead of pivotal readout - MSN
Tenax Therapeutics: A Binary Bet With Heavy Downside Likely (NASDAQ:TENX) - Seeking Alpha
Tenax Therapeutics (TENX): Cantor Fitzgerald Initiates Coverage with Overweight Rating | TENX Stock News - GuruFocus
Top Cypherpunk Technologies (CYPH) Competitors 2026 - MarketBeat
Published on: 2026-03-17 23:42:59 - baoquankhu1.vn
Tenax stock wins bullish view at Cantor (TENX:NASDAQ) - Seeking Alpha
Cantor Fitzgerald initiates Tenax Therapeutics stock with overweight rating - Investing.com
Cantor Fitzgerald initiates Tenax Therapeutics stock with overweight rating By Investing.com - Investing.com India
Cantor Fitzgerald Initiates Coverage on Tenax Therapeutics (NASDAQ:TENX) - MarketBeat
Tenax Therapeutics (TENX) Gains Momentum with Phase 3 Trial - GuruFocus
Boothbay Fund Management LLC Purchases Shares of 352,206 Tenax Therapeutics, Inc. $TENX - MarketBeat
This Ingredion Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Sahm
Tenax Therapeutics (TENX) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Guggenheim Raises Price Target for TENX, Maintains Buy Rating | - GuruFocus
Guggenheim Issues Positive Forecast for Tenax Therapeutics (NASDAQ:TENX) Stock Price - MarketBeat
What is Lifesci Capital’s Forecast for TENX Q1 Earnings? - Defense World
What is Lifesci Capital's Forecast for TENX Q1 Earnings? - MarketBeat
Trading Systems Reacting to (TENX) Volatility - Stock Traders Daily
Logos Global Management LP Acquires 615,000 Shares in Tenax Therapeutics Inc - GuruFocus
Tenax Therapeutics, Inc. (NASDAQ:TENX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Tenax Therapeutics (NASDAQ:TENX) Raised to "Strong-Buy" at Lifesci Capital - MarketBeat
Analysts Offer Insights on Healthcare Companies: Tenax Therapeutics (TENX), RegenXBio (RGNX) and Foghorn Therapeutics (FHTX) - The Globe and Mail
TENX PE Ratio & Valuation, Is TENX Overvalued - Intellectia AI
William Blair Maintains Outperform on Tenax Therapeutics (TENX) March 2026 - Meyka
Tenax Therapeutics Inc (TENX) Q4 Loss Widens, But Beats Estimates - AlphaStreet
Christopher Giordano Discloses Investment at Tenax Therapeutics with 6.79% Stake - TradingView
Tenax Therapeutics (TENX) CEO reports 6.79% beneficial ownership stake - Stock Titan
Tenax Therapeutics Inc (TENX) Reports Q4 Earnings - AlphaStreet
TENX: LEVEL trial enrollment completed early; global expansion and regulatory preparations advancing - TradingView
Tenax Therapeutics stock gains as trial enrollment complete By Investing.com - Investing.com Canada
Tenax Therapeutics Achieves Phase 3 LEVEL Study Patient Target and Reports 2025 Financial Results; Topline Data Expected Q3 2026 - Minichart
Tenax Therapeutics stock holds at Outperform at Leerink Partners By Investing.com - Investing.com Canada
Tenax Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Tenax Therapeutics Reports Q4 Loss - National Today
Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Investing News Network
Tenax Therapeutics, Inc. 2025 Annual Report: Business Strategy, Risk Factors, Clinical Pipeline, and Regulatory Challenges - Minichart
Tenax Therapeutics 2025 Financials: Q4 Loss Beats Analyst EstimatesNews and Statistics - IndexBox
TENAX Therapeutics 10-K: Net loss $52.6M, NOL $56.4M, cash runway into 2027 - TradingView
Tenax Therapeutics (NASDAQ: TENX) outlines Phase 3 PH-HFpEF strategy - Stock Titan
TENX: LEVEL and LEVEL-2 trials advanced, net loss widened, cash reserves support operations through 2027 - TradingView
Tenax Therapeutics (TENX) Completes Patient Enrollment for Phase 3 LEVEL Study - GuruFocus
Tenax Therapeutics (NASDAQ: TENX) ramps Phase 3 TNX-103 trials and widens 2025 loss - Stock Titan
Tenax Therapeutics: Q4 Earnings Snapshot - marketscreener.com
Tenax Therapeutics Q4 net loss widens on higher R&D expenses - TradingView
Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides ... - Bluefield Daily Telegraph
TENX Technical Analysis & ETF Price Forecast - Intellectia AI
Tenax Therapeutics Inc (TENX) 財務データ
収益
当期純利益
現金流量
EPS
Tenax Therapeutics Inc (TENX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Rich Stuart | Chief Medical Officer |
Dec 08 '25 |
Buy |
10.10 |
2,500 |
25,250 |
5,000 |
| Rich Stuart | Chief Medical Officer |
Dec 04 '25 |
Buy |
9.20 |
2,500 |
22,998 |
2,500 |
| Rich Stuart | Chief Medical Officer |
Dec 03 '25 |
Buy |
9.08 |
1,500 |
13,618 |
2,766 |
| Rich Stuart | Chief Medical Officer |
Dec 02 '25 |
Buy |
9.01 |
1,000 |
9,006 |
1,266 |
| Giordano Christopher Thomas | CEO |
Nov 18 '25 |
Buy |
7.75 |
1,612 |
12,500 |
1,612 |
| Giordano Christopher Thomas | CEO |
Nov 20 '25 |
Buy |
7.59 |
538 |
4,083 |
2,605 |
| Giordano Christopher Thomas | CEO |
Nov 19 '25 |
Buy |
7.51 |
455 |
3,417 |
2,067 |
| MCGAULEY THOMAS | Interim CFO |
Nov 17 '25 |
Buy |
7.25 |
6,000 |
43,490 |
5,000 |
| MCGAULEY THOMAS | Interim CFO |
Nov 17 '25 |
Buy |
7.34 |
2,000 |
14,674 |
2,000 |
| Almenoff June Sherie | Director |
Nov 18 '25 |
Buy |
7.52 |
1,900 |
14,280 |
1,993 |
0.99%
3.03%
大文字化:
|
ボリューム (24 時間):